59 studies found for:    Open Studies | "Pigmentation Disorders"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds
Conditions: Surgical Wound;   Hypo-pigmented Skin
Intervention: Device: Momelan Technologies Epidermal Graft Harvesting System
2 Not yet recruiting Nevus Doctor Clinical Decision Support
Conditions: Nevus;   Melanoma
Intervention: Device: Nevus doctor program
3 Unknown  Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011
Condition: Solar Lentigines
Intervention: Other: skin whitening cosmetic product
4 Unknown  Azelaic Acid Versus Hydroquinone in Melasma
Condition: Melanosis
Interventions: Drug: azelaic acid gel;   Drug: hydroquinone cream
5 Unknown  Treatment and Complication of Bath PUVA in Vitiligo
Condition: Vitiligo
Intervention: Device: Bath PUVA
6 Recruiting Clinical and Basic Investigations Into Erdheim Chester Disease
Conditions: Myelofibrosis;   Gaucher Disease;   Pulmonary Fibrosis;   Hermansky-Pudlak Syndrome (HPS);   Cancer
Intervention:
7 Unknown  Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model
Condition: Vitiligo
Intervention: Procedure: foreskin from healthy adults
8 Recruiting Evaluation of an Herbal-Based De-Pigmenting System
Conditions: Melasma;   Hyperpigmentation
Interventions: Other: Herbal depigmenting agent (Epionce);   Drug: Hydroquinone
9 Unknown  Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Condition: Advanced Systemic Mastocytosis
Intervention: Drug: Cladribine and pegylated interpheron alpha-2a
10 Not yet recruiting The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism
Conditions: Ocular Albinism (OA);   Oculocutaneous Albinism (OCA)
Interventions: Dietary Supplement: Lutein plus Zeaxanthin;   Dietary Supplement: Placebo
11 Recruiting Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism
Conditions: Albinism;   Oculocutaneous Albinism;   Foveal Hypoplasia;   Hypopigmentation;   Nystagmus
Intervention:
12 Unknown  Molecular Mechanisms and Diagnosis of Mastocytosis
Condition: Mastocytosis
Intervention:
13 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions: Smouldering Systemic Mastocytosis;   Indolent Systemic Mastocytosis;   Cutaneous Mastocytosis With Handicap;   Mastocytosis
Interventions: Drug: masitinib (AB1010);   Drug: placebo
14 Unknown  Prevalence of Carbohydrate Intolerance in Lean and Obese Children
Conditions: Obesity;   Glucose Intolerance;   Diabetes;   Acanthosis Nigricans
Intervention:
15 Recruiting Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo
Condition: Vitiligo
Intervention: Drug: Triamcinolone Acetonide
16 Recruiting Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)
Condition: Vitiligo
Interventions: Drug: topical tacrolimus treatment;   Drug: topical pimecrolimus treatment;   Drug: local mometasone furoate treatment;   Drug: cold cream
17 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
18 Unknown  Audiological Disturbances in Vitiligo
Conditions: Vitiligo;   Hearing Loss
Intervention:
19 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Interventions: Drug: brentuximab vedotin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
20 Recruiting A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years